Background. Diseases caused by atherosclerosis play the most important role in mortality and morbidity worldwide. Serum adipocyte fatty acid binding protein (A-FABP) seems to be a new promising marker to determine the risk of atherosclerosis.
INTRODUCTION
Diseases caused by atherosclerosis such as stroke or myocardial infarction play the most important role in mortality and morbidity worldwide, especially in highly developed countries. New markers for onset of atherosclerosis are sought. Serum adipocyte fatty acid binding protein (A-FABP) seems to be a new promising marker to determine the risk of atherosclerosis.
Adipocyte fatty acid-binding protein (A-FABP) is a member of the fatty acid binding protein super family, accounting for approximately 6% of total cellular proteins in mature adipocytes 1 . It is also present in macrophages, which possess similar functions to adipocytes, modulated by proliferator-activated receptor-c agonists and oxidized low density lipoproteins 2 . Recently, ectopic expression and function of A-FABP in several other types of cells and tissues (for example endothelial cells of capillaries and small veins in the heart and kidney) have been demonstrated 3 . A-FABP-deficient mice are protected from insulin resistance, hyperglycemia, and atherosclerosis 4, 5 . It has been demonstrated that A-FABP is released into the human blood stream 6 .
Human serum A-FABP levels are significantly higher in men than in women, possi bly because of the larger amount of body fat in women 6, 7 . Its circulating levels are elevated in patients with obesity and other components of the metabolic syndrome, including adverse lipid profiles, hyperglycemia and hypertension, independently of sex, age and adiposity 6, [8] [9] [10] . Serum A-FABP levels correlate also positively with markers of endothelial dysfunction, and coronary atherosclerotic burden [11] [12] [13] [14] [15] .
High concentration of A-FABP at baseline was an indepen dent predictor for the development of metabolic syndrome during a five-year follow-up period in a Chinese population 16 . A 10-year prospective study also showed that high level of A-FABP at baseline independently predicted the develop ment of type 2 diabetes 17 . Associations of A-FABP levels with the development of left ventricular (LV) hypertrophy and with systolic and diastolic cardiac dysfunction have also been reported [18] [19] [20] [21] . These findings support the role of A-FABP as a key pro-inflammatory mediator that links obesity with cardiovascular damage and atherosclerosis.
The aim of this cross sectional study was to evaluate relationships between serum A-FABP levels in studied individuals and to assess the possibility of modeling intima media thickness of common carotid artery (C-IMT) by A-FABP levels and other observed characteristics.
METHODS

Study design and subjects
The study cohort included asymptomatic dyslipidemic Czech subjects and healthy volunteers who underwent C-IMT measurement in the Lipid Centre of the Department of Internal Medicine III, University Hospital Olomouc, Czech Republic. The medical history was obtained and physical examination was performed, including measurement of waist circumference, body mass index (BMI), and systolic and diastolic pressure (SBP, DBP). Patients with the following conditions were excluded from the study: secondary hyperlipidemia (hypothyroidism, renal or hepatic diseases, nephrotic syndrome), hypolipidemic therapy in the previous 6 weeks, hormone therapy, acute infection or trauma and history of clinically manifested atherosclerosis (coronary artery disease, cerebrovascular disease or peripheral arterial disease). Individuals who met these criteria (72 subjects, 31 men and 41 women) were divided into three groups: 17 hyperlipidemic patients with the metabolic syndrome (MetS+, men/women: 8/9, mean age: 47.9 ± 14.5 years), 34 hyperlipidemic patients without the metabolic syndrome (MetS-, men/women: 16/18, mean age: 40.8 ± 15.5 years) and 21 normolipidemic healthy subjects (men/women: 7/14, mean age: 47.0 ± 17.3 years) who served as a control group. A diagnosis of metabolic syndrome was based on a modified version of the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III) and defined as at least three of the following at baseline: waist circumference (men > 102 cm, women > 88 cm), triglycerides (TG) ≥ 1.7 mmol/L, HDL cholesterol (men < 1.04 mmol/L , women < 1.30 mmol/L), blood pressure ≥ 130/≥ 85 mm Hg and fasting glucose ≥ 6.1 mmol/L. Presence of metabolic syndrome was evaluated at the time of first patient examination in the lipid center. The study was reviewed and approved by the Ethics Committee of the Faculty of Medicine and Dentistry and University Hospital Olomouc. Informed consent was obtained from all participants.
Laboratory analysis
All subjects were assessed after overnight fasting for at least 12 h. Venous blood samples were obtained and after centrifugation, the serum was used for analysis. Routine serum biochemical parameters were analyzed in the day of blood collection, concentrations of adipokines were measured in the sample aliquots stored at -80 °C, no longer than 6 months. Total cholesterol (TC), TG and high density lipoprotein cholesterol (HDL-C) were determined enzymatically on Modular SWA system (Roche, Basel, Switzerland). HDL-C was measured by direct method without precipitation of apoB containing lipoproteins. Low density lipoprotein cholesterol (LDL-C) levels were calculated using Friedewald formula. Non-HDL-cholesterol (nonHDL-C) was calculated as TC -HDL-C. Concentration of apoB and apolipoprotein A1 (apoA1) were determined immunoturbidimetrically using Tina-Quant ApoB and ApoA-1 kits (Roche, Basel, Switzerland). Glucose was measured using GOD-PAP method (Roche, Basel, Switzerland). A-FABP was determined using Human A-FABP ELISA kit (Biovendor Laboratory Medicine Inc., Brno, Czech Republic).
Measurement of carotid IMT
High-resolution B-mode ultrasound (Philips Sonos 5500, 2004) was used to measure the IMT of the common carotid arteries (CCA). Linear array transducers with frequency of 10 MHz were used. Anterolateral approach was used to longitudinally image the right and left CCA. This image was displayed just before the widening of the bulb. When an optimal longitudinal image of the far wall of the CCA in the region of 1 cm proximally from the bulb was obtained, it was frozen on the R wave according to a simultaneous ECG and video tapered. Three video records were made on both CCA. C-IMT measurements were processed off-line using the software Image-Pro plus (Version 4.0, Media -Cybernetics, Silver Spring, USA). The region under evaluation was the CCA wall 1-2 cm distant proximally from the mentioned border. The average of all mean C-IMT of three frozen images of both sides was chosen as outcome variable. Plaque was defined as a focal protrusion into the lumen with a thickness of at least 50% more than adjacent intima-media complex. Subjects with this atherosclerotic plaque in the evaluated region were not included in the study. The measurement of C-IMT was made without knowledge of laboratory results.
Statistical analysis
Statistical analyses were performed with software R, ver. 3.4.2. (ref. 22 ). Data were summarized as means and standard deviation and analysed using ANOVA, Student's t-test, Kruskall-Wallis or Wilcoxon test. In the case of more than two groups, multiple comparisons were done with Tukey test, resp. Nemenyi test. Categorical variables were analyzed with Pearson's chi-square test, or Fisher's exact test. Multiple linear models of IMT values were built for all individuals' data and also for subset of healthy controls and dyslipidemic patients without metabolic syndrome (MetS-). Feature selection was based on LASSO (Least Absolute Shrinkage and Selection Operator) regression results for lambda parameter obtained as minimal value in 5-fold cross-validation process for each analyzed set of data (R package glmnet) (ref. 23 ). Linear model for dyslipidemic patients with metabolic syndrome was not performed due to empty non-zero coefficient set of Lasso regression results for these subset of patients. In suitable cases (existence of non-significant regressors), a stepwise selection process was also performed. In case of healthy subset, based on fit diagnostic plot (Cook's distance), one leverage observation was excluded in final model.
RESULTS
The demographic, clinical and biochemical characteristic of the investigated groups are summarized in Table 1 and Fig. 1, 2 . Individuals with MetS (MetS+) had highest BMI and waist circumference and expected unfavorable lipid and lipoprotein profiles (elevated TC, TG, and non-HDL-C, ApoB, ApoB/ApoA1 ratio and decreased HDL-C and ApoA1) and signs of insulin resistance (increased levels of insulin and C-peptide). A-FABP concentrations in this group were significantly higher in comparison with both MetS-and controls. Differences in A-FABP levels between MetS-and controls were not significant. Similar results were found in C-IMT (significantly thicker C-IMT in MetS+ than in MetS-and in controls, but no difference between MetS-and controls). Using multiple linear regression models of C-IMT values for all individuals data and also for subset of healthy controls and dyslipidemic patients without metabolic syndrome (MetS-) A-FABP level was not revealed as an important predictor of C-IMT. Only age, gender, waist circumference, nonHDL cholesterol levels and ApoB/ ApoA1 ratio were important regressors of C-IMT see Table 2 , 3, 4) .
DISCUSSION
In the current study we confirmed the well-established risk profile of individuals with MetS. They had unfavorable lipid and lipoprotein profiles, as well as increased parameters of insulin resistence. A-FABP concentrations in this group were significantly higher in comparison with both MetS-and controls. This finding is consistent with the results of previous studies and our previous reports 12 .
It has been reported that increased circulating A-FABP levels are associated with obesity, insulin resistance, type 2 diabetes, hypertension, cardiac dysfunction, and atherosclerosis 6, 14, 16, 17, 24, 25 . High concentration of A-FABP at baseline was an indepen dent predictor for the development of metabolic syndrome during a five-year follow-up period in a Chinese population 16 . A 10-year prospective study also showed that high level of A-FABP independently predicted the develop ment of type 2 diabetes 17 .
Relationship between serum A-FABP and C-IMT was observed in some previous studies. Hao Y. et al. revealed a positive correlation between serum A-FABP and subclinical atherosclerosis in a cohort of Chinese pre-and postmenopausal women with normal glucose tolerance 26 . A study of Yeung et al. reported that serum A-FABP levels were strongly associated with C-IMT in women including both hyperglycemia and normal glucose tolerance 14 . These findings support the notion that circulating A-FABP is not only a potent bio marker but also plays an important role, as an adipokine, in the development of atherosclerosis.
From this point of view is surprising, that A-FABP was not found as a predictor of C-IMT in our multiple linear regression models in contrast to classical factors as age, gender or waist circumference , even when all subjects were included in the analysis. This is in contrast with study of Yeng et al. 14 , where multiple regression analysis had identified serum A-FABP together with age and hypertension to be independent risk factors related to C-IMT in female subjects. The study cohort consisted of many more subjects than ours (479 vs. 72 individuals). The other factor is separate testing of men and women. There was a difference in the race of participiants, too (Chinese vs.Caucasian). Other limitations of our study are as follows. First, we used a cross-sectional study design and therefore we could not establish a cause-and-effect relationship between A-FABP and C-IMT. Second, participants of our study were Caucasians, so our findings cannot be generalized to other ethnicities.
One other possible explanation for our findings is that the proatherosclerotic effects of conventional risk factors were stronger than A-FABP and probably outweighed its effect on carotid atherosclerosis. Therefore, future studies should be prospective and include a large number of cases.
One confounding factor in this study was the impossibility of using a linear model for dyslipidemic patients with metabolic syndrome due to empty non-zero coefficient set of Lasso regression results for this subset of patients. We only can speculate about the small number of individuals in MetS+ group and about the heterogeneity of these patients In any case, this phenomenon is surprising and we have no explanation for it.
An interesting fact is the ApoB/ApoA1 ratio as an important predictor of C-IMT in dyslipidemic patients without metabolic syndrome.
The apoB/apoA1 ratio has been reported to be associated with the metabolic syndrome (MetS), and it may be a more convenient biomarker in MetS prediction, especially in Chinese populations 27, 28 . In a single study on older healthy volunteers, Panayiotou et al. demonstrated that high ApoB/ApoA1 ratio is associated with early atherosclerosis 29 . In linear regression analysis, the ApoB/ ApoA1 ratio was significantly associated with all the ultrasonic measurements of early atherosclerosis (among others C-IMT). In our study it is the first observation of the influence of ApoB/ApoA1 on C-IMT in dyslipidemic individuals.
CONCLUSION
Our data, in agreement with previous animal and clinical studies, revealed higher A-FABP levels and C-IMT in Czech dyslipidemic individuals with metabolic syndrome. This supports the role of A-FABP in the development of the metabolic syndrome and probably atherosclerosis. In contrast, to these findings A-FABP was not an important predictor of C-IMT in dyslipidemic patients. This finding may be attributed to the overwhelming effect of other risk factors of atherosclerosis in dyslipidemic individuals. One interesting finding is revealing of ApoB/ApoA1 ratio as an important predictor of common C-IMT in dyslipidemic patients without metabolic syndrome.
Further investigations are needed to identify model regressors especially for very heterogenic groups of dyslipidemic patients with metabolic syndrome.
